These results demonstrate that the marked anti-tumour efficacy observed upon combining olaparib, AZD1775 and STING agonist is a result of increased tumour immunogenicity, tumour infiltration and activation of DCs, as well as tumour infiltration and interferon signalling of CD8 T cells. This evidence concerns the gene CD8A and neoplasm.